Mounjaro: The #1 most prescribed branded T2D medication for adults in the U.S.¹

Superior A1C reduction across 6 trials^a

^aIn 6 studies of glycemic control with a primary endpoint at 30 weeks (pediatric patients ≥10 years old) and 40 weeks or 52 weeks (adult patients), mean reductions in A1C with Mounjaro ranged from 1.8-2.1% for the 5 mg dose (pediatric and adult patients), 1.7-2.4% for the 10 mg dose (pediatric and adult patients), and 1.7-2.4% for the 15 mg dose (adult patients); and for comparator arms, mean reduction in A1C in pediatric patients was 0.2% for placebo, and in adults were 0.1% and 0.9% for placebo, 1.9% for Ozempic® 1 mg, 1.3% for Tresiba®, and 1.4% for insulin glargine. p<0.05 for superiority vs comparator, adjusted for multiplicity.²

Discover the Data

Unmatched weight results across 6 trials^b

Mounjaro is not indicated for weight loss.² Weight-related changes were secondary endpoints.²

^bIn clinical studies with Mounjaro, weight-related change from baseline was a secondary endpoint. In 6 studies of glycemic control with primary endpoint at 30 weeks(pediatric patients ≥10 years old) and 40 weeks or 52 weeks(adult patients), mean percent reductions in BMI in pediatric patients were 6.9% for the 5 mg dose, 10.8% for the 10 mg dose, and 0.5% for placebo; and mean reductions in body weight in adults ranged from 12-17 lb for the 5 mg dose, 15-21 lb for the 10 mg dose, and 17-25 lb for the 15 mg dose; and for comparator arms, mean changes were -2 lb and +4 lb for placebo, -13 lb for Ozempic 1 mg, +4 lb for Tresiba, and +4 lb for insulin glargine. p<0.05 for superiority vs comparator, adjusted for multiplicity.²

Mounjaro has 92% preferred^† access across commercial and Part D plans nationally*

*Represents Commercial and Medicare Formulary data.

^†Preferred means product is covered on formulary at the preferred brand tier or lowest branded copay tier designation with or without restrictions. Source: Managed Markets Insight & Technology (MMIT), LLC as of 10/15/2025, and is subject to change without notice by a health plan or state. Please contact the plan or state for the most current information. This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employers and employer groups may also offer additional benefit designs which may be different than described. PA process consistency is ensured by consistent prior authorization and step therapy requirements, measured by MMIT.

Coverage & Savings